John L Pfail1, Andrew B Katims1, Parissa Alerasool2, John P Sfakianos3. 1. Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, 1425 Madison Avenue, 6th Floor, New York City, NY, 10029, USA. 2. School of Medicine, New York Medical College, Valhalla, NY, USA. 3. Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, 1425 Madison Avenue, 6th Floor, New York City, NY, 10029, USA. John.Sfakianos@icahn.mssm.edu.
Abstract
PURPOSE: Patients harboring high-grade non-muscle-invasive bladder cancer (NMIBC) experience high rates of both recurrence and progression. Currently, few treatment options besides cystectomy exist for this at-risk population, especially those with BCG-unresponsive disease. The purpose of this review is to present the current status and describe future directions of immunotherapy in NMIBC. METHODS: The PubMed and Google Scholar databases were searched for articles pertaining to immunotherapy in NMIBC. Relevant planned and ongoing clinical trials were identified using www.ClinicalTrials.gov . Published randomized control trials, reviews, other retrospective and prospective studies deemed relevant were used in this review paper. RESULTS: Novel immunotherapies used in the treatment of high-grade NMIBC and BCG-unresponsive disease allow patients more options and have the potential to reduce the need for radical cystectomy. Currently, several options target the programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) axis as this mechanism of immunotherapy has been shown to be effective in several cancers, including bladder, melanoma, and lung cancers. In addition, other immunotherapy options for the treatment of NMIBC include viral gene therapies, interleukin-15 superagonists, small molecule inhibitors of indoleamine (2,3)-dioxygenase 1, and vaccines. CONCLUSIONS: The current landscape of immunotherapy in bladder cancer is rapidly evolving, with much literature pertaining to muscle-invasive and metastatic disease. However, the implementation of these treatment options in high-grade NMIBC may allow patients to avoid life-altering surgery. Reliable biomarkers for response are needed to further select patients who may benefit from such therapies.
PURPOSE:Patients harboring high-grade non-muscle-invasive bladder cancer (NMIBC) experience high rates of both recurrence and progression. Currently, few treatment options besides cystectomy exist for this at-risk population, especially those with BCG-unresponsive disease. The purpose of this review is to present the current status and describe future directions of immunotherapy in NMIBC. METHODS: The PubMed and Google Scholar databases were searched for articles pertaining to immunotherapy in NMIBC. Relevant planned and ongoing clinical trials were identified using www.ClinicalTrials.gov . Published randomized control trials, reviews, other retrospective and prospective studies deemed relevant were used in this review paper. RESULTS: Novel immunotherapies used in the treatment of high-grade NMIBC and BCG-unresponsive disease allow patients more options and have the potential to reduce the need for radical cystectomy. Currently, several options target the programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) axis as this mechanism of immunotherapy has been shown to be effective in several cancers, including bladder, melanoma, and lung cancers. In addition, other immunotherapy options for the treatment of NMIBC include viral gene therapies, interleukin-15 superagonists, small molecule inhibitors of indoleamine (2,3)-dioxygenase 1, and vaccines. CONCLUSIONS: The current landscape of immunotherapy in bladder cancer is rapidly evolving, with much literature pertaining to muscle-invasive and metastatic disease. However, the implementation of these treatment options in high-grade NMIBC may allow patients to avoid life-altering surgery. Reliable biomarkers for response are needed to further select patients who may benefit from such therapies.
Authors: Giacomo Novara; James W F Catto; Timothy Wilson; Magnus Annerstedt; Kevin Chan; Declan G Murphy; Alexander Motttrie; James O Peabody; Eila C Skinner; Peter N Wiklund; Khurshid A Guru; Bertram Yuh Journal: Eur Urol Date: 2015-01-02 Impact factor: 20.096
Authors: Marko Babjuk; Andreas Böhle; Maximilian Burger; Otakar Capoun; Daniel Cohen; Eva M Compérat; Virginia Hernández; Eero Kaasinen; Joan Palou; Morgan Rouprêt; Bas W G van Rhijn; Shahrokh F Shariat; Viktor Soukup; Richard J Sylvester; Richard Zigeuner Journal: Eur Urol Date: 2016-06-17 Impact factor: 20.096
Authors: M Rouprêt; Y Neuzillet; A Masson-Lecomte; P Colin; E Compérat; F Dubosq; N Houédé; S Larré; G Pignot; P Puech; M Roumiguié; E Xylinas; A Méjean Journal: Prog Urol Date: 2016-11 Impact factor: 0.915
Authors: Richard J Sylvester; Adrian P M van der Meijden; Willem Oosterlinck; J Alfred Witjes; Christian Bouffioux; Louis Denis; Donald W W Newling; Karlheinz Kurth Journal: Eur Urol Date: 2006-01-17 Impact factor: 20.096
Authors: Richard J Sylvester; Maurizio A Brausi; Wim J Kirkels; Wolfgang Hoeltl; Fernando Calais Da Silva; Philip H Powell; Stephen Prescott; Ziya Kirkali; Cees van de Beek; Thierry Gorlia; Theo M de Reijke Journal: Eur Urol Date: 2009-12-18 Impact factor: 20.096
Authors: Simone Albisinni; Marco Moschini; Ettore Di Trapani; Francesco Soria; Andrea Mari; Atiqullah Aziz; Jeremy Teoh; Ekaterina Laukhtina; Keiichiro Mori; David D'Andrea; Diego M Carrion; Wojciech Krajewski; Mohammad Abufaraj; Alessia Cimadamore; Wei Shen Tan; Ronan Flippot; Jonathan Khalifa; Kimberly Gonsette; Benjamin Pradere Journal: World J Urol Date: 2021-06-02 Impact factor: 4.226